What one share of Cellectar Biosciences holds
We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate ™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects.
Cellectar Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.77 |
|---|---|
| Cash and investments | $4.12 |
| Book value | $3.62 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$550.86 | $0.96 | −$458.04 | — | $252.84 |
| 2021 | — | −$130.35 | $0.76 | −$122.72 | — | $135.91 |
| 2022 | — | −$135.18 | $0.96 | −$108.20 | — | $21.64 |
| 2023 | — | −$104.99 | $2.12 | −$81.60 | — | −$21.92 |
| 2024 | — | −$41.89 | $0.08 | −$38.52 | — | $8.97 |
| 2025 | — | −$8.35 | $0.00 | −$8.87 | — | $1.89 |
Common questions about Cellectar Biosciences
How much does one share of Cellectar Biosciences earn?
Over the last 12 months, Cellectar Biosciences lost $3.77 for each share.
Does Cellectar Biosciences pay a dividend?
Cellectar Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Cellectar Biosciences’s book value per share?
Cellectar Biosciences’s book value is $3.62 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Cellectar Biosciences have?
Each share of Cellectar Biosciences has $4.12 of cash and investments, as of June 30, 2026.
Has Cellectar Biosciences bought back shares?
Cellectar Biosciences’s share count rose about 10095% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.